Analyst Ratings For BioLife Solutions Inc (NASDAQ:BLFS)
Today, B. Riley set its price target on BioLife Solutions Inc (NASDAQ:BLFS) to $23.00 per share.
There are 3 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.
The current consensus rating on BioLife Solutions Inc (NASDAQ:BLFS) is Buy with a consensus target price of $17.6667 per share, a potential 13.99% downside.
Some recent analyst ratings include
- 8/10/2018-BioLife Solutions Inc (NASDAQ:BLFS) had its Buy rating reiterated by Northland Securities with a $18.00 price target
- 7/5/2017-BioLife Solutions Inc (NASDAQ:BLFS) gets upgraded to Buy by Janney Montgomery Scott with a price target of $5.00
Recent Insider Trading Activity For BioLife Solutions Inc (NASDAQ:BLFS)
BioLife Solutions Inc (NASDAQ:BLFS) has insider ownership of 38.50% and institutional ownership of 16.34%.
- On 7/18/2018 Greef Roderick De, CFO, sold 10,000 with an average share price of $20.00 per share and the total transaction amounting to $200,000.00.
- On 7/16/2018 Michael Rice, CEO, sold 12,540 with an average share price of $19.90 per share and the total transaction amounting to $249,546.00.
- On 7/9/2018 Thomas Girschweiler, Director, sold 285,714 with an average share price of $11.37 per share and the total transaction amounting to $3,248,568.18.
- On 7/9/2018 Walter Villiger, Major Shareholder, sold 214,286 with an average share price of $11.37 per share and the total transaction amounting to $2,436,431.82.
- On 6/18/2018 Michael Rice, CEO, sold 12,540 with an average share price of $12.89 per share and the total transaction amounting to $161,640.60.
- On 6/13/2018 Andrew G Hinson, Director, sold 10,000 with an average share price of $11.25 per share and the total transaction amounting to $112,500.00.
- On 6/1/2018 Joseph C Schick, Director, sold 6,858 with an average share price of $10.07 per share and the total transaction amounting to $69,060.06.
About BioLife Solutions Inc (NASDAQ:BLFS)
BioLife Solutions, Inc. develops, manufactures, and markets patented tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced, and delayed-onset cell damage and death. The company offers HypoThermosol FRS, a hypothermic storage and shipping media product to mitigate temperature-induced molecular cell stress responses that occur during chilling and re-warming of biologics, intermediate products, and final cell products intended for research and clinical applications; and CryoStor cryopreservation freeze media products to mitigate temperature-induced molecular cell stress responses during freezing and thawing. It also provides BloodStor freeze media products, such as BloodStor 55-5 and BloodStor 100 for cryopreservation of stem and other cells isolated from umbilical cord and peripheral blood, and bone marrow; and cell thawing media, which offers Dextran and saline for washing cryopreserved cells and tissues to dilute or remove cryoprotectants. In addition, the company provides custom product formulation and packaging services; and contract aseptic manufacturing formulation, filling, and finishing services for liquid media products. It markets its products to the regenerative medicine, bio-banking, and drug discovery markets, including hospital-based stem cell transplant centers, pharmaceutical companies, cord blood and adult stem cell banks, and hair transplant centers, as well as suppliers of cells to the drug discovery, toxicology testing, and diagnostic markets. The company markets and sells its products directly using its sales force, as well as through biolifesolutions.com; and through various regional distributors. BioLife Solutions, Inc. was founded in 1987 and is headquartered in Bothell, Washington.
Recent Trading Activity for BioLife Solutions Inc (NASDAQ:BLFS)
Shares of BioLife Solutions Inc closed the previous trading session at 20,54 +0,82 4,16 % with 19.7 shares trading hands.